Healthcare Private Placement and M&A Transactions Review Week Ending Jan 19, 2025

Truveta: The company raised $320 million of Series C venture funding from Illumina and Regeneron Pharmaceuticals on January 13, 2025, putting the company’s pre-money valuation at $1.2 billion. The company is a developer of a health data platform designed to aggregate data across multiple healthcare systems to provide medical insights.

Colossal Laboratories & Biosciences: The company raised $200 million of Series C venture funding in a deal led by TWG Global, Mark Walter and Thomas Tull on January 15, 2025, putting the company’s pre-money valuation at $10 billion. The company is an operator of a bioscience and genetic engineering company building new technologies to advance the field of genomics.

Ashvattha Therapeutics: The company raised an estimated $119 million of Series B venture funding in a deal led by Huadong Medicine Company, Tribe Capital and Natural Capital (US) on January 13, 2025, putting the company’s pre-money valuation at an estimated $191 million. Evolution VC Partners, Plum Alley Investments, Deep Ventures (Venture Capital), A-Level Capital, Socii Capital, Johns Hopkins Technology Ventures, Kingsley Advani, Kyle Wang, Sakya Duvvuru, Brady Anthony-Brumfield, Preetham Gaddam, Sand Hill Angels and Helios Capital (New York) also participated in the round. The company is a developer of hydroxyl dendrimer therapeutics designed to meet the unmet medical needs in oncology, ophthalmology and inflammatory diseases.

Umoja Biopharma: The company raised $100 million of Series C venture funding in a deal led by DCVC Bio and Double Point Ventures on January 14, 2025, putting the company’s pre-money valuation at $320 million. SoftBank Investment Advisers, Cormorant Asset Management, Alexandria Venture Investments, Qiming Venture Partners USA, K2 HealthVentures, Myeloma Investment Fund, MPM BioImpact, University of Minnesota, ARK Investment Management, RTW Investments, CaaS Capital Management and Emerson Collective also participated in the round. The company is a provider of in vivo CAR T-cell therapeutics and RACR-induced cytotoxic lymphocytes intended to transform cancer treatment.

Studycast: The company received $80 million of development capital from PSG on January 16, 2025. The company is a developer of a medical imaging workflow platform designed to transform manual data entry into an automatic data population.

Normunity: The company raised $75 million of Series B venture funding in a deal led by Enavate Sciences and Samsara BioCapital on January 13, 2025. Sanofi Ventures, Taiho Ventures, Regeneron Ventures, Pfizer Ventures, YK Bioventures, Hongshang Capital, Osage University Partners, Connecticut Innovations and Canaan Partners also participated in the round. The company is an operator of a biotechnology business intended to create precision immuno-oncology medicines.

Rivus Pharmaceuticals: The company raised $57 million of venture funding from undisclosed investors on January 16, 2025. The company is a developer of controlled metabolic accelerators designed to improve cardio-metabolic health.

Bioptimus: The company raised $41 million of venture funding in a deal led by Cathay Innovation on January 14, 2025. Hitachi Ventures, Sunrise Capital, Andera Partners, Pomifer Capital, Boom Capital Ventures, Sofinnova Partners and Bpifrance also participated in the round. The company is a developer of a universal artificial intelligence foundation model designed to drive scientific research and biotechnological innovation.

Solera: The company raised $40 million of Series E venture funding in a deal led by Health Care Service Corporation on January 14, 2025, putting the company’s pre-money valuation at $140 million. Cobalt Ventures, Horizon Mutual Holdings, Adams Street Partners, and other undisclosed investors also participated in the round. The company is a developer of a healthcare platform designed to address chronic conditions through lifestyle and behavioral interventions.

Hinge Bio: The company received $30.6 million of development capital from Point72 Asset Management, Lightswitch Capital, Thornapple River Capital, Ridgeback Capital, InVivium Capital, and other undisclosed investors on January 15, 2025. The transaction values the company at $46 million. The company is an operator of a biotech platform designed to develop therapeutics that address the problems of resistance, inadequate efficacy, and side effects in the fields of autoimmunity, cancer, inflammatory disease and infectious disease.

Perceptive: The company raised $30 million of venture funding from Pacific Dental Services, Dental Innovation Alliance and Y Combinator on January 15, 2025. Edward Zuckerberg and Lubos Menus also participated in the round. The company is a developer of an AI-powered robotic system designed to improve the accuracy and speed of restorative dental procedures.

Robeauté: The company raised EUR 27 million of Series A venture funding in a deal led by Plural, Cherry Ventures and Kindred Ventures on January 14, 2025. Brainlab, APEX Ventures, Phoenix Court, and Think.Health also participated in the round. The company is a developer of a sub-millimetric medical device designed to diagnose and treat neuropathologies.

Owlstone Medical: The company raised $27 million of Series E venture funding in a deal led by Ventura Capital on January 15, 2025. Aviva Ventures, Horizons Ventures, Bill & Melinda Gates Foundation, and other undisclosed investors also participated in the round. The company is a developer of breathalyzer designed to focus on non-invasive diagnostics for the early detection of disease, and on precision medicine.

Advanced Bifurcation Systems: The company raised $20.8 million of venture funding in the form of SAFE notes from Brandon Holdings and other undisclosed investors on January 17, 2025. The company is a developer of a stenting device intended to treat bifurcation lesions in coronary angioplasties.

Pictor Labs: The company raised $20.6 million of Series B venture funding in a deal led by Insight Partners on January 16, 2025, putting the company’s pre-money valuation at $64 million. M Ventures, Laboratory Corporation of America, and other undisclosed investors also participated in the round. The company is a developer of a digital imaging platform designed to conduct histopathology.

AiTA: The company raised $10 million of Series C venture funding from undisclosed investors on January 13, 2025, putting the company’s pre-money valuation at $330 million. The company is a developer of an integrated Micro-Electro-Mechanical Systems (MEMS) augmented biology platform.

hc1 Insights: The company raised $6.5 million of venture funding in a deal led by Health Cloud Capital on January 13, 2025. Arsenal Capital Partners, Beyond Capital, A1 Health Ventures, and other undisclosed investors also participated in the round. The company is a developer of a personalized cloud-based healthcare relationship management platform.

First Ascent Biomedical: The company raised $6 million of venture funding in a deal led by Vidal-Duart Enterprises on January 13, 2025. Techstars and other undisclosed investors also participated in the round. The company is a developer of a drug prediction platform designed for oncology utilizing AI and therapy-resistant cell technologies which delivers both treatment planning for cancer patients and drug development tools for pharma.

ImmunoGenesis: The company raised $5.75 million of venture funding from undisclosed investors on January 15, 2025. The company is a developer of immuno-oncology therapeutics for cold tumor treatments.

Intracellular Therapies / Johnson & Johnson: The company reached a definitive agreement to be acquired by Johnson & Johnson for $14.6 billion on January 13, 2025. Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system.

Curio Bioscience / Takara Bio USA: The company reached a definitive agreement to be acquired by Takara Bio USA for $6.35 billion on January 15, 2025. The company is a developer of genomic technologies designed to understand complex cellular biology.

Life Molecular Imaging / Lantheus Medical Imaging: The company, a subsidiary of Alliance Medical, reached a definitive agreement to be acquired by Lantheus Medical Imaging for $350 million on January 13, 2025. The company is a developer of novel PET tracers designed for molecular imaging research and development services.

Antibe Therapeutics / Taro Pharmaceutical Industries: The company reached a definitive agreement to be acquired by Taro Pharmaceutical Industries, a subsidiary of Sun Pharmaceutical Industries, for an undisclosed amount on January 16, 2025. Antibe Therapeutics Inc provides a proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions.

Banner Life Sciences / Cycle pharma: The company was acquired by Cycle pharma for an undisclosed amount on January 13, 2025. The company is an operator of a clinical-stage pharmaceutical company focused on the treatment of relapsing forms of multiple sclerosis.

Decoy Therapeutics / Salarius Pharmaceuticals: The company reached a definitive agreement to be acquired by Salarius Pharmaceuticals for an undisclosed amount on January 13, 2025. The company is a developer of high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs.

endox Feinwerktechnik / Alleima: The company was acquired by Alleima, a subsidiary of Sandvik, for an undisclosed amount on January 14, 2025. The company is a developer of medical technology and precision engineering instruments designed for endoscopic applications.

IBA Lifesciences / Cube Biotech: The company was acquired by Cube Biotech, via its financial sponsor ARCHIMED, through an LBO on January 13, 2025 for an undisclosed amount. The company is a manufacturer of protein purification and analysis products intended for life sciences.

Konica Minolta REALM / SB Tempus: SB Tempus reached a definitive agreement to acquire the Company, a subsidiary of Konica Minolta Business Innovation Center, for an undisclosed amount on January 14, 2025. The company is a manufacturer of a cancer genome profiling system for the medical industry.

KT Health / Bridges Consumer Healthcare: The company was acquired by Bridges Consumer Healthcare, via its financial sponsor Charlesbank Capital Partners, through an LBO on January 14, 2025 for an undisclosed amount. The company is a designer, developer, and distributor of sports medicine products such as therapeutic kinesiology tape and other products for pain relief and muscle support.

Suvoda / Greenphire: The company entered into a definitive agreement to be acquired by Greenphire, via its financial sponsor Thoma Bravo, through an LBO on January 13, 2025 for an undisclosed amount. The company is a developer of randomization and trial supply management software intended for the areas of oncology, central nervous system and rare diseases.

Tyber Medical / Montagu Private Equity: The company was acquired by Montagu Private Equity through an LBO on January 13, 2025 for an undisclosed amount. The company is an orthopedic device manufacturer providing rapid access to portfolio enhancing, regulatory approved, orthopedic implants within the spine and extremity/trauma markets.

Upfront / Health Catalyst: The company reached a definitive agreement to be acquired by Health Catalyst for $86 million on January 14, 2025. The company is a developer of a patient navigation platform designed to book virtual or in-person care.

Whitecap Biosciences / Bausch + Lomb: The company was acquired by Bausch + Lomb for an undisclosed amount on January 13, 2025. The company is a developer of novel therapies for ophthalmic diseases with a focus on glaucoma, and other serious eye diseases.